Liver cancer trial with doxorubicin Transdrug suspended on safety
This article was originally published in Scrip
Executive Summary
BioAlliance Pharmahas suspended its Phase II/III trial of doxorubicin Transdrug in inoperable liver cancer on the advice of the study's data safety monitoring board (DSMB) which found more frequent and severe pulmonary adverse events than expected.